Cargando…
Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China
During the outbreak of the novel coronavirus disease (COVID-19), the Chinese government took a series of public health measures to tackle the outbreak and recommended six traditional Chinese medicine (TCM) evolved formulas, collectively referred to as “3-drugs-3-formulas”, for the treatment. In this...
Autores principales: | Wu, Jieya, Sun, Baoguo, Hou, Li, Guan, Fulan, Wang, Liyuan, Cheng, Peikwen, Scobell, Sophia, Cheng, Yung-Chi, Lam, Wing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947616/ https://www.ncbi.nlm.nih.gov/pubmed/33716728 http://dx.doi.org/10.3389/fphar.2020.615287 |
Ejemplares similares
-
YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy
por: Lam, Wing, et al.
Publicado: (2023) -
YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity
por: Lam, Wing, et al.
Publicado: (2023) -
Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)
por: Lam, Wing, et al.
Publicado: (2018) -
Majority of Chinese Medicine Herb Category “Qing Re Yao” Have Multiple Mechanisms of Anti-inflammatory Activity
por: Guan, Fulan, et al.
Publicado: (2018) -
The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)
por: Lam, Wing, et al.
Publicado: (2014)